Researchers have discovered a key vulnerability across all major variants of the SARS-CoV-2 virus, including the recently emerged BA.1 and BA.2 Omicron subvariants. The weakness can be targeted by neutralizing antibodies, potentially paving the way for treatments that would be universally effective across variants.
